Drug Trial News

RSS

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

Poorer cancer patients less likely to have access to experimental drug trials

Among people with advanced cancer, poorer patients are less likely to be referred for clinical trials of experimental drugs, a new study from the UK suggests.

6 Dec 2012

Tenofovir DF safe and effective in treating adolescents with HBV

A recent clinical trial found that the adult antiviral drug, tenofovir disoproxil fumarate (tenofovir DF), is safe and effective in treating adolescents with hepatitis B virus (HBV). Trial results published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), show that tenofovir DF suppressed HBV in 89% of pediatric participants.

6 Dec 2012

University of Florida initiates enrollment in SPI-1005 Phase II trial for sensorineural hearing loss

The University of Florida (UF) has started enrolling subjects in a new study testing the oral drug developed by Sound Pharmaceuticals, Inc. (SPI-1005) to prevent hearing loss caused by loud music. Loud music or noise can induce temporary and permanent auditory threshold shifts (TTS or PTS).

6 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

RXi commences RXI-109 Phase 1 study for management of surgical scars and keloids

RXi Pharmaceuticals Corporation, today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.

5 Dec 2012

Cabozantinib effectively treats prostate cancer spread to bones

A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.

5 Dec 2012

Virginia Women's Center to participate in new HPV and cervical cancer vaccine clinical trial

Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.

4 Dec 2012

Very high dose prednisolone reasonable alternative to ACTH for children with infantile spasms

A pilot study to determine the best hormonal treatment for infantile spasms (IS) that may lead to changes in prescribing practices for hormone therapy is being presented for the first time at the American Epilepsy Society's 66th Annual Meeting in San Diego California.

4 Dec 2012

Antidepressants in normal dosage may positively impact mood and seizure frequency

Epilepsy and depression are common co-morbidities. Concern for the potential of certain antidepressants to induce seizures has led to under-treating depression and anxiety disorders in epilepsy patients. Research presented today at the 66th American Epilepsy Society meeting suggests that antidepressants in normal dosage may have a positive impact on both mood and seizure frequency.

4 Dec 2012

Certain patients with prostate cancer may benefit from Provenge clinical trial

Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

4 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

3 Dec 2012

NeuroVive announce results from CicloMulsion Phase I trial on cardiac reperfusion injury

NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion demonstrates bioequivalence and improved tolerability when compared with Sandimmune Injection.

3 Dec 2012

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.

30 Nov 2012

Combination of chemotherapy and selumetinib shows promise against NSCLC

A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.

30 Nov 2012

GM1 ganglioside effectively treats patients with Parkinson's disease

Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial, Thomas Jefferson University researchers report in a new study published online November 28 in the Journal of the Neurological Sciences.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Drug Trial News

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Poorer cancer patients less likely to have access to experimental drug trials

Tenofovir DF safe and effective in treating adolescents with HBV

University of Florida initiates enrollment in SPI-1005 Phase II trial for sensorineural hearing loss

Sickle cell disease trial completes phase 3 patient enrollment

RXi commences RXI-109 Phase 1 study for management of surgical scars and keloids

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

Cabozantinib effectively treats prostate cancer spread to bones

Virginia Women's Center to participate in new HPV and cervical cancer vaccine clinical trial

Very high dose prednisolone reasonable alternative to ACTH for children with infantile spasms

Antidepressants in normal dosage may positively impact mood and seizure frequency

Certain patients with prostate cancer may benefit from Provenge clinical trial

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Merck commences MK-8931 Phase II/III trial in Alzheimer's

NeuroVive announce results from CicloMulsion Phase I trial on cardiac reperfusion injury

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Combination of chemotherapy and selumetinib shows promise against NSCLC

GM1 ganglioside effectively treats patients with Parkinson's disease

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News